Jamie Hartmann-Boyce, MA, DPhil: Medical, Diabetes Research in COVID-19


Jamie Hartmann-Boyce, MA, DPhil, discusses how medical researchers have adapted to the increased pace associated with the COVID-19 era.

While still in the midst of the pandemic, the coronavirus disease 2019 (COVID-19) era has been one the likes of which medicine and society has never known.

From the disease itself to the impact on health care systems and everything in between, COVID-19 has left an indelible mark across every corner of the globe. At the forefront of this disease and the public response to it are medical researchers.

While they may not be on the frontlines in hospitals and care centers, medical researchers have been responsible for compiling, aggregating, and interpreting mountains of data at a breakneck pace for months now. Providing invaluable data for clinicians and the general public, the work of medical researchers has gone from databases to journals and into clinical practice faster than ever before.

An example of this is the recent article published in Diabetes Care providing an overview of potential associations between COVID-19 and diabetes. Led by Jamie Hartmann-Boyce, MA, DPhil, senior research fellow and departmental lecturer at the Nuffield Department of Primary Care Health Sciences of University of Oxford, the article outlines multiple aspects of diabetes and risk factor management, as well as the effects of COVID-19 on the mental health of these patients.

In an interview with Endocrinology Network, Hartmann-Boyce pointed out the current pandemic is unique in that it demonstrates how the actions and reactions of different nations have allowed for a more accelerated review period. This accelerated period has allowed for greater interpretation of information in a real-time manner.

For more on the role of medical research during the COVID-19 era, Endocrinology Network reached out to Hartmann-Boyce to learn how the field of medical research and those conducting that research have been impacted by the ongoing pandemic.

This study, “Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters,” was published in Diabetes Care.

Related Videos
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Daniel Gaudet, MD, PhD | Credit: American College of Cardiology
Laxmi Mehta, MD | Credit: American Heart Association
© 2024 MJH Life Sciences

All rights reserved.